[company_age]10.0[/company_age][employees]11-50 employees[/employees][funding]series_unknown[/funding][description]Oxeia Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for mild traumatic brain injury (mTBI), commonly known as concussion, and related neuro-metabolic dysfunction. The company stands out for its focus on treating the underlying causes of concussions, rather than just managing symptoms. Oxeia's leadership team comprises experienced professionals with deep expertise in medical, scientific, and business aspects of drug development and concussion research, making them uniquely positioned to bring effective treatments to market.[/description][ps]OXE103, a drug for treating mTBI and related neuro-metabolic dysfunction.[/ps]